CEBPA Full Gene Mutation Analysis Test
About CEBPA Full Gene Mutation Analysis Test
| Field | Value |
|---|---|
| Also Known As | CEBPA Mutation Analysis, CEBPA Gene Sequencing, CCAAT/Enhancer Binding Protein Alpha Mutation Test |
| Sample Type | Bone marrow and peripheral blood |
| Fasting Required | No fasting required |
| Report Time | 12 days |
| Recommended For | Men, women, and children of all ages with suspected or confirmed acute myeloid leukaemia (AML) |
| Price | Starting at ₹8,400 |
What is a CEBPA Full Gene Mutation Analysis Test?
The CEBPA Full Gene Mutation Analysis test examines the CEBPA gene (CCAAT/Enhancer Binding Protein Alpha) for disease-causing variants. It is used to classify and assess prognosis in patients diagnosed with, or suspected to have, acute myeloid leukaemia (AML). The test is performed using bone marrow and peripheral blood samples analysed by Sanger sequencing.
This test may also be called CEBPA Gene Sequencing or CEBPA Mutation Analysis.
What Does a CEBPA Full Gene Mutation Analysis Test Measure?
The CEBPA Full Gene Mutation analysis looks at specific regions of the CEBPA gene to identify changes that affect how blood cells develop and mature. The following parameters are assessed.
| Parameter | What It Looks For |
|---|---|
| CEBPA mutation status | Whether any disease-causing variant is present in the CEBPA gene |
| Mutation type | Whether a single (monoallelic) or double (biallelic) mutation is present |
| N-terminal mutations | Changes in regions that help switch genes on or off, leading to abnormal protein production |
| C-terminal (bZIP) mutations | Changes in the DNA-binding region that disrupt normal protein function |
Because this is a qualitative genetic test, results are reported as mutation detected or not detected, along with details of the mutation type and location if found.
Why is a CEBPA Full Gene Mutation Analysis Test Done?
Doctors order this test when a patient has signs or symptoms that suggest a blood cell disorder, particularly AML. The results help classify the disease and guide decisions about treatment.
Common Symptoms That May Require This Test
Patients are often referred for this test when they present with one or more of the following symptoms.
- Persistent tiredness and weakness
- Pale skin or unusual breathlessness
- Frequent infections that do not resolve
- Easy bruising or unexplained bleeding, including nosebleeds and bleeding gums
- Night sweats and high temperature
- Unexplained weight loss
- Swollen lymph nodes
Conditions This Test Can Help Detect
The CEBPA Full Gene Mutation analysis test is used to investigate the following conditions.
- Acute myeloid leukaemia (AML), particularly in patients with normal chromosome patterns (normal karyotype)
- AML with biallelic CEBPA mutations, which is recognised as a distinct entity with a favourable outlook under the WHO 2016 classification
- Familial (inherited) AML, where a CEBPA variant is passed down through generations
How to Prepare and What to Expect
Preparation for this test is straightforward. There is no fasting required and no special dietary restrictions.
Do You Need to Fast?
No. Fasting is not required before this test. You may eat and drink as normal on the day of sample collection.
Practical Tips Before Your Test
Keep the following points in mind before your appointment.
- Bring a detailed clinical history report, including your symptoms, previous test results, and family history, as this is required for the test
- Inform your doctor about all medications and supplements you are currently taking
- Genetic counselling may be recommended before and after testing; speak to your doctor if you have questions
- Wear comfortable, loose-fitting clothing that allows easy access to your arm for blood collection
- Samples must be kept refrigerated (2 to 8 degrees Celsius) and should never be frozen
Step-by-Step Procedure
This test requires two types of samples: peripheral blood and bone marrow. Here is what to expect during each collection.
Peripheral Blood Collection
- A trained phlebotomist will clean the skin on the inside of your elbow.
- A needle is used to draw a small blood sample from a vein into a sodium heparin (green top) tube or EDTA (lavender top) tube.
- The needle is removed, and light pressure is applied to the site with a small cotton pad.
- The blood sample is labelled and stored at 2 to 8 degrees Celsius for dispatch to the laboratory.
Bone Marrow Collection
- A doctor will numb the area (usually the back of the hip bone) with a local anaesthetic before the procedure.
- A special needle is inserted into the bone to withdraw a small amount of bone marrow into a sodium heparin (green top) tube.
- The sample is stored correctly and dispatched to the lab along with your clinical history.
Both samples are analysed by Sanger sequencing in the laboratory, and results are typically available within 12 days.
Factors That Can Affect Accuracy
Several factors may affect the quality or interpretation of test results.
- Poor sample quality or insufficient DNA from the sample
- A low proportion of leukaemic cells in the sample (low variant allele fraction)
- Improper storage or delayed transport of samples
- Absence of accompanying clinical history, which is required for result interpretation
Understanding Your CEBPA Full Gene Mutation Analysis Test Results
Results from this test should always be reviewed by a qualified haematologist or oncologist. The table below summarises how results are typically reported.
| Parameter | Normal | Abnormal |
|---|---|---|
| CEBPA mutation status | No mutation detected | Mutation detected |
| Mutation type | Not applicable | Single (monoallelic) or double (biallelic) |
| Mutation location | Not applicable | N-terminal or C-terminal (bZIP) domain |
A result showing no mutation detected means no disease-causing variant was found in the CEBPA gene. This does not rule out AML, as additional testing is required for a complete diagnosis. When a mutation is detected, double (biallelic) mutations are associated with a more favourable outlook compared to single mutations. CEBPA mutations in the bZIP domain are classified in the favourable risk group under current international guidelines.
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
Since this test examines genetic mutations, there are no lifestyle changes that directly alter the result. However, the following general guidance applies.
- Attend all follow-up appointments with your haematologist or oncologist as scheduled.
- Ensure complete and accurate reporting of family history to help your doctor assess inherited risk.
- Ask your doctor about genetic counselling if a mutation is detected, particularly if there is a family history of AML.
Lupin Diagnostics CEBPA Full Gene Mutation Analysis Test Price
The CEBPA Full Gene Mutation analysis test starts at ₹8,400 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre or an authorised collection point, as home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 8400 |
| CHENNAI | 8400 |
| HYDERABAD | 8400 |
| KOLKATA | 8400 |
| NAVI MUMBAI | 8400 |
| PUNE | 8400 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book your CEBPA Full Gene Mutation analysis test online at Lupin Diagnostics.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The CEBPA gene produces a protein called CCAAT/Enhancer Binding Protein Alpha, which controls how certain blood cells grow and mature. When this gene carries a mutation, the normal development of white blood cells is disrupted, which can lead to AML. The CEBPA Full Gene Mutation analysis test identifies these changes to help classify the disease.
A double (biallelic) mutation means both copies of the CEBPA gene are affected. Patients with double mutations tend to have a more favourable prognosis. A single (monoallelic) mutation, affecting only one copy, does not carry the same prognostic advantage. Your doctor will explain what the finding means for your specific situation.
CEBPA mutations are found in approximately 6% to 15% of newly diagnosed AML cases. They are more common in patients whose leukaemia cells show normal chromosome patterns, where the rate may be as high as 15% to 18%.
No. This CEBPA Full Gene Mutation analysis is a one-time diagnostic test used at the time of initial diagnosis. It is not designed to monitor how well treatment is working. Other specialised tests, such as minimal residual disease (MRD) testing, are used for treatment monitoring.
Yes, in some cases. Most CEBPA mutations arise spontaneously in leukaemia cells and are not inherited. However, familial AML can occur when a CEBPA variant is passed down through generations. If more than one family member has AML, genetic counselling is advisable.
The CEBPA mutation analysis test procedure involves Sanger sequencing, and interpreting the results correctly depends on knowing the patient's clinical background, previous test results, and family history. Without this information, the laboratory cannot provide a fully contextual report.
Doctors typically order CEBPA mutation analysis together with FLT3-ITD and NPM1 mutation testing for newly diagnosed AML. These tests together provide a fuller picture of disease risk and help guide the most appropriate course of management.
CEBPA Full Gene Mutation Analysis Test
